Lv61
1790 积分 2024-01-12 加入
Myasthenia Gravis Impairment Index
2个月前
已完结
Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study
3个月前
已完结
Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets
3个月前
已完结
Clinical characteristics of anti‐AChR‐MuSK‐LRP4 antibody‐negative myasthenia gravis in China
3个月前
已完结
Treatment of autoimmune myasthenia gravis
3个月前
已完结
Therapeutic options in autoimmune myasthenia gravis
3个月前
已完结
Maintenance immunosuppression in myasthenia gravis
3个月前
已完结
Maintenance immunosuppression in myasthenia gravis, an update
4个月前
已完结
Maintenance immunosuppression in myasthenia gravis, an update
5个月前
已完结
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of 2 different treatment approaches
5个月前
已完结
皖公网安备34019202002308
